Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or
‘the Company’) a pharmaceutical company developing proprietary
medicinal cannabinoid products and psychedelic assisted
psychotherapies for unmet needs is pleased to announce that its
subsidiary, Clarion Clinics Group Pty Ltd, is now accepting direct
registration of interest in treatment from potential clients via
its website at clarionclinics.com ahead of its planned Q3 opening.
People who have an interest in treatment from
Clarion can now register and request further information on the
Clarion website. “This is the first step in the process towards
receiving treatment and we anticipate that there will be a high
level of interest in our leading-edge treatments”, Peter Widdows,
Incannex Director responsible for Clarion said.
Clarion’s first clinic is located on the Yarra Riverfront in the
Melbourne suburb of Abbotsford, close to the city centre. It’s a
purpose-designed facility with seven treatment rooms and other
facilities conducive to psychedelic-assisted therapy. The fit-out
of the premises is expected to be completed before the end of
August, facilitating opening shortly thereafter.
“A lot of thought went into the design of the
clinic, as both practical and aesthetic considerations are very
important for this type of treatment. It’s imperative that clients
feel welcome, comfortable and safe. We wanted the design of the
space to support a sense of calm and a positive mindset, as we know
these things contribute to better treatment outcomes.” Sean
O’Carroll, Clarion Director and Head of Psychotherapy, said.
Clarion’s clinical leadership of Dr. Paul Liknaitzky, Prof.
Suresh Sundram and Sean O’Carroll have developed a bespoke
nine-month long treatment program, designed to maximise the chance
of positive results for clients.
“Our evidence-informed treatment protocols, professional team,
and experience within research trials will soon be in service of
our clients and the best possible treatment we can provide,” Dr.
Paul Liknaitzky, Clarion Director and Chief Scientific Officer,
commented.
In order to be able to prescribe the psychedelic compounds to be
used in Clarion’s PAT protocol, psychiatrists must be approved
under the TGA’s Authorised Prescriber Scheme. Once Clarion‘s
approvals have been received, treatments can commence.
“The recent guidance from the Royal Australian and New Zealand
College of Psychiatrists in regards to PAT are part of the process
towards the safe and effective provision of clinical psychedelic
care to the many people who are without adequate treatment options
for serious mental health conditions,” Professor Suresh Sundram,
Clarion Director and Head of Psychiatry, said.
Australian health authorities estimate that 12% of Australians
will suffer from PTSD at some point in their lifetime, and 1.5% of
the population (390,000 people) have a PTSD diagnosis at any given
time. Certain groups, for example people who serve in the defence
force, military veterans, first responders, and certain minority
groups make up a disproportionate share of people who experience
this debilitating mental health disorder.
Along with the many sufferers of PTSD, it’s estimated that 26.5%
of the just over one million Australians who suffer depression
(280,000 people) do not adequately respond to standard
treatments.
“The term ‘treatment-resistant’ has misleading connotations,
implying that all avenues have been exhausted and that front-line
treatments work well for everyone else. In reality, neither are
typically true. For people who have suffered with certain
conditions that have not responded to available treatments,
psychedelic-assisted therapies may provide substantial improvements
to negative symptoms and quality of life. At Clarion Clinics, our
aim is to achieve the best outcomes possible using psychedelic
therapies, through tailored and extended protocols and a brilliant
team,” Dr. Paul Liknaitzky said.
This announcement has been approved for
release to ASX by the Incannex Board of Directors.
About Incannex Healthcare Limited
Incannex is a clinical stage pharmaceutical
development company that is developing unique medicinal cannabis
pharmaceutical products and psychedelic medicine therapies for the
treatment of obstructive sleep apnoea (OSA), traumatic brain injury
(TBI) and concussion, lung inflammation (ARDS, COPD, asthma,
bronchitis), rheumatoid arthritis, inflammatory bowel disease,
anxiety disorders, addiction disorders, and pain, among other
indications.
U.S. FDA approval and registration, subject to
ongoing clinical success, is being pursued for each drug and
therapy under development. Each indication under investigation
currently has no, or limited, existing registered pharmacotherapy
(drug) treatments available to the public and represent major
global economic opportunities to Incannex and its shareholders.
Incannex has a strong patent filing strategy in
place as it develops its products and therapies in conjunction with
its medical and scientific advisory board and partners. The Company
holds 19 granted patents and 30 pending patent applications.
Incannex is listed on the Australian Stock Exchange (ASX) with
stock code “IHL” and has American Depository Shares listed on
NASDAQ under code “IXHL”.
Website:
www.incannex.com.au Investors:
investors@incannex.com.au
Forward-looking statementsThis
press release contains "forward-looking statements" within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are made as of the date they were first issued and were
based on current expectations and estimates, as well as the beliefs
and assumptions of management. The forward-looking statements
included in this press release represent Incannex's views as of the
date of this press release. Incannex anticipates that subsequent
events and developments may cause its views to change. Incannex
undertakes no intention or obligation to update or revise any
forward-looking statements, whether as of a result of new
information, future events or otherwise. These forward-looking
statements should not be relied upon as representing Incannex's
views as of any date after the date of this press release.
Contact Information:
Incannex Healthcare LimitedMr
Joel LathamManaging Director and Chief Executive Officer+61 409 840
786joel@incannex.com.au
Investor Relations Contact – United States
Alyssa Factor Edison Group
+1 (860) 573 9637afactor@edisongroup.com
Incannex Healthcare (NASDAQ:IXHL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Incannex Healthcare (NASDAQ:IXHL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024